Clinical Trial: Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome
Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title:
Brief Summary:
- The study will be a prospective open labelled double blinded randomized controlled study.
- The study will be conducted on patients admitted to Department of Hepatology from 2012 to 2014 at Institute of Liver and Biliary Sciences, New Delhi
- Patients diagnosed as having clinical or subclinical hepatopulmonary syndrome will be started on oral pentoxifylline therapy 400 mg thrice daily for 12 weeks.
- Patients not responding to this therapy will be given divided into 2 arms with one arm receiving additional Tab Rifaximin 400 mg thrice daily or placebo for 12 weeks.
Detailed Summary:
Sponsor: Institute of Liver and Biliary Sciences, India
Current Primary Outcome: Complete response after 3 months of treatment [ Time Frame: 3 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Development of serious adverse effects leading to withdrawal of the drug [ Time Frame: 3 months ]
Original Secondary Outcome: Same as current
Information By: Institute of Liver and Biliary Sciences, India
Dates:
Date Received: August 29, 2012
Date Started: September 2012
Date Completion: September 2014
Last Updated: December 16, 2013
Last Verified: December 2012
